MicroPort Scientific Corporation Provides Consolidated Earnings Guidance for the Full Year Ended December 31, 2021
rhythm management business, the neurovascular business and the heart valve business, contribution from new product launches, and the increase in elective surgeries from the easing of the COVID-19 pandemic. During the Reporting Period, the Group recorded loss attributable to equity shareholders of the Company of between approximately USD 275 million and USD 285 million, as compared with a loss of USD 191 million for the same period of last year.